600789.SH
鲁抗医药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 7.19
−1.91%Year over year
Reported trailing growth
- Revenue
- -6.5%
- EBITDA
- —
- EBIT
- -68.1%
- EPS
- -80.1%
- Free cash flow
- +1900.1%
- Operating cash flow
- +213.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +0.9%
- EBITDA
- +6.9%
- EBIT
- +2.6%
- Net income
- -6.6%
- EPS
- -9.1%
- Free cash flow
- +182.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026